Echo IQ (ASX:EIQ) secured a definitive exclusive data licensing agreement with Advara HeartCare, according to a Thursday filing with the Australian bourse.
The agreement, which is for an initial three-year term with an option to extend for another three years, provides the company access to between 500,000 and 1 million de-identified echocardiography studies and associated relevant clinical datasets, the filing said.
Financial terms were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.